Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2012

01-06-2012 | Research Articles

Preliminary clinical study of weekly recombinant human endostatin as a hypoxic tumour cell radiosensitiser combined with radiotherapy in the treatment of NSCLC

Authors: Xiao-Dong Jiang, Yun Qiao, Peng Dai, Jin Wu, Da-An Song, Shi-Qiu Li, Yue-Wei Fan

Published in: Clinical and Translational Oncology | Issue 6/2012

Login to get access
Metadata
Title
Preliminary clinical study of weekly recombinant human endostatin as a hypoxic tumour cell radiosensitiser combined with radiotherapy in the treatment of NSCLC
Authors
Xiao-Dong Jiang
Yun Qiao
Peng Dai
Jin Wu
Da-An Song
Shi-Qiu Li
Yue-Wei Fan
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Clinical and Translational Oncology / Issue 6/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0825-z

Other articles of this Issue 6/2012

Clinical and Translational Oncology 6/2012 Go to the issue

Research Articles

Biological markers of cisplatin resistance in advanced testicular germ cell tumours

Brief Research Articles

Relevance of breast cancer subtypes for magnetic resonance imaging response monitoring during neoadjuvant chemotherapy

Research Articles

Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study

Editorial

Evolution of tumour biology upon progression. Do we know our enemy?

Educational Series

Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles

Special Article

Functions and workload of medical oncologists in Spain
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits